Cargando…

Kinetics and durability of transgene expression after intrastriatal injection of AAV9 vectors

Understanding the kinetics and durability of AAV-mediated transgene expression in the brain is essential for conducting basic neuroscience studies as well as for developing gene therapy approaches for CNS diseases. Here, we characterize and compare the temporal profile of transgene expression after...

Descripción completa

Detalles Bibliográficos
Autores principales: Hollidge, Bradley S., Carroll, Hayley B., Qian, Randolph, Fuller, Madison L., Giles, April R., Mercer, Andrew C., Danos, Olivier, Liu, Ye, Bruder, Joseph T., Smith, Jared B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9702554/
https://www.ncbi.nlm.nih.gov/pubmed/36452163
http://dx.doi.org/10.3389/fneur.2022.1051559
_version_ 1784839685419302912
author Hollidge, Bradley S.
Carroll, Hayley B.
Qian, Randolph
Fuller, Madison L.
Giles, April R.
Mercer, Andrew C.
Danos, Olivier
Liu, Ye
Bruder, Joseph T.
Smith, Jared B.
author_facet Hollidge, Bradley S.
Carroll, Hayley B.
Qian, Randolph
Fuller, Madison L.
Giles, April R.
Mercer, Andrew C.
Danos, Olivier
Liu, Ye
Bruder, Joseph T.
Smith, Jared B.
author_sort Hollidge, Bradley S.
collection PubMed
description Understanding the kinetics and durability of AAV-mediated transgene expression in the brain is essential for conducting basic neuroscience studies as well as for developing gene therapy approaches for CNS diseases. Here, we characterize and compare the temporal profile of transgene expression after bilateral injections into the mouse striatum of rAAV9 encoding GFP under the control of either a ubiquitous promoter (CAG), or the neuron-specific human synapsin (hSyn) and CamKII promoters. GFP protein expression with the CAG promoter was highest at 3 weeks, and then decreased to stable levels at 3 and 6 months. Surprisingly, GFP mRNA levels continued to increase from 3 weeks to 3 months, despite GFP protein expression decreasing during this time. GFP protein expression with hSyn increased more slowly, reaching a maximum at 3 months, which was equivalent to protein expression levels from CAG at that time point. Importantly, transgene expression driven by the hSyn promoter at 6 months was not silenced as previously reported, and GFP mRNA was continuing to rise even at the final 6-month time point. Thus, hSyn as a promoter for transgene expression demonstrates long-term durability but may require more time after vector administration to achieve steady-state levels. Because CAG had the highest GFP protein expression in our comparison, which was at 3 weeks post administration, the early kinetics of transgene expression from CAG was examined (1, 2, 5, and 10 days after injection). This analysis showed that GFP protein expression and GFP mRNA increased during the first 3 weeks after administration. Interestingly, vector DNA rapidly decreased 10-fold over the first 3 weeks following injection as it assembled into stable circular episomes and concatemers. Surprisingly, the processing of vector genomes into circular episomes and concatemers was continually dynamic up to 3 months after injection. These results provide novel insight into the dynamic processing of vector genomes and promoter-specific temporal patterns of transgene expression in the brain.
format Online
Article
Text
id pubmed-9702554
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-97025542022-11-29 Kinetics and durability of transgene expression after intrastriatal injection of AAV9 vectors Hollidge, Bradley S. Carroll, Hayley B. Qian, Randolph Fuller, Madison L. Giles, April R. Mercer, Andrew C. Danos, Olivier Liu, Ye Bruder, Joseph T. Smith, Jared B. Front Neurol Neurology Understanding the kinetics and durability of AAV-mediated transgene expression in the brain is essential for conducting basic neuroscience studies as well as for developing gene therapy approaches for CNS diseases. Here, we characterize and compare the temporal profile of transgene expression after bilateral injections into the mouse striatum of rAAV9 encoding GFP under the control of either a ubiquitous promoter (CAG), or the neuron-specific human synapsin (hSyn) and CamKII promoters. GFP protein expression with the CAG promoter was highest at 3 weeks, and then decreased to stable levels at 3 and 6 months. Surprisingly, GFP mRNA levels continued to increase from 3 weeks to 3 months, despite GFP protein expression decreasing during this time. GFP protein expression with hSyn increased more slowly, reaching a maximum at 3 months, which was equivalent to protein expression levels from CAG at that time point. Importantly, transgene expression driven by the hSyn promoter at 6 months was not silenced as previously reported, and GFP mRNA was continuing to rise even at the final 6-month time point. Thus, hSyn as a promoter for transgene expression demonstrates long-term durability but may require more time after vector administration to achieve steady-state levels. Because CAG had the highest GFP protein expression in our comparison, which was at 3 weeks post administration, the early kinetics of transgene expression from CAG was examined (1, 2, 5, and 10 days after injection). This analysis showed that GFP protein expression and GFP mRNA increased during the first 3 weeks after administration. Interestingly, vector DNA rapidly decreased 10-fold over the first 3 weeks following injection as it assembled into stable circular episomes and concatemers. Surprisingly, the processing of vector genomes into circular episomes and concatemers was continually dynamic up to 3 months after injection. These results provide novel insight into the dynamic processing of vector genomes and promoter-specific temporal patterns of transgene expression in the brain. Frontiers Media S.A. 2022-11-14 /pmc/articles/PMC9702554/ /pubmed/36452163 http://dx.doi.org/10.3389/fneur.2022.1051559 Text en Copyright © 2022 Hollidge, Carroll, Qian, Fuller, Giles, Mercer, Danos, Liu, Bruder and Smith. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neurology
Hollidge, Bradley S.
Carroll, Hayley B.
Qian, Randolph
Fuller, Madison L.
Giles, April R.
Mercer, Andrew C.
Danos, Olivier
Liu, Ye
Bruder, Joseph T.
Smith, Jared B.
Kinetics and durability of transgene expression after intrastriatal injection of AAV9 vectors
title Kinetics and durability of transgene expression after intrastriatal injection of AAV9 vectors
title_full Kinetics and durability of transgene expression after intrastriatal injection of AAV9 vectors
title_fullStr Kinetics and durability of transgene expression after intrastriatal injection of AAV9 vectors
title_full_unstemmed Kinetics and durability of transgene expression after intrastriatal injection of AAV9 vectors
title_short Kinetics and durability of transgene expression after intrastriatal injection of AAV9 vectors
title_sort kinetics and durability of transgene expression after intrastriatal injection of aav9 vectors
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9702554/
https://www.ncbi.nlm.nih.gov/pubmed/36452163
http://dx.doi.org/10.3389/fneur.2022.1051559
work_keys_str_mv AT hollidgebradleys kineticsanddurabilityoftransgeneexpressionafterintrastriatalinjectionofaav9vectors
AT carrollhayleyb kineticsanddurabilityoftransgeneexpressionafterintrastriatalinjectionofaav9vectors
AT qianrandolph kineticsanddurabilityoftransgeneexpressionafterintrastriatalinjectionofaav9vectors
AT fullermadisonl kineticsanddurabilityoftransgeneexpressionafterintrastriatalinjectionofaav9vectors
AT gilesaprilr kineticsanddurabilityoftransgeneexpressionafterintrastriatalinjectionofaav9vectors
AT mercerandrewc kineticsanddurabilityoftransgeneexpressionafterintrastriatalinjectionofaav9vectors
AT danosolivier kineticsanddurabilityoftransgeneexpressionafterintrastriatalinjectionofaav9vectors
AT liuye kineticsanddurabilityoftransgeneexpressionafterintrastriatalinjectionofaav9vectors
AT bruderjosepht kineticsanddurabilityoftransgeneexpressionafterintrastriatalinjectionofaav9vectors
AT smithjaredb kineticsanddurabilityoftransgeneexpressionafterintrastriatalinjectionofaav9vectors